REGENERON PHARMACEUTICALS, INC. Deferred Income Tax Expense (Benefit)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Deferred Income Tax Expense (Benefit) of -$785.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-04
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2014-12-31 was -$1.98M.
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2014-09-30 was -$15.83M.
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2014-06-30 was -$21.95M, a 141.42% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for the quarter ending 2014-03-31 was -$5.76M, a 114.58% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2025 was -$785.40M.
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2024 was -$757.30M.
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2023 was -$837.80M.
- REGENERON PHARMACEUTICALS, INC. deferred income tax expense (benefit) for fiscal 2022 was -$746.40M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 3 month as first filed | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 6 month as first filed | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 9 month as first filed | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$785.40M 10-K · filed 2026-02-04 | |||||||
| 2024-12-31 | -$757.30M 10-K · filed 2026-02-04 | |||||||
| 2023-12-31 | -$837.80M 10-K · filed 2026-02-04 | |||||||
| 2022-12-31 | -$746.40M 10-K · filed 2025-02-05 | |||||||
| 2021-12-31 | -$147.10M 10-K · filed 2024-02-05 | |||||||
| 2020-12-31 | $75.60M 10-K · filed 2023-02-06 | |||||||
| 2019-12-31 | -$130.60M 10-K · filed 2022-02-07 | |||||||
| 2018-12-31 | -$140.00M 10-K · filed 2021-02-08 | |||||||
| 2017-12-31 | $319.00M 10-K · filed 2020-02-07 | $319.01M 10-K · filed 2018-02-08 | ||||||
| 2016-12-31 | -$360.10M 10-K · filed 2019-02-07 | -$360.08M 10-K · filed 2017-02-09 | ||||||
| 2015-12-31 | -$130.09M 10-K · filed 2018-02-08 | |||||||
| 2014-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | -$17.81M derived: sum of 2 quarters · filed 2017-02-09 | -$39.77M derived: sum of 3 quarters · filed 2017-02-09 | -$45.53M 10-K · filed 2017-02-09 | -$51.29M 10-K · filed 2015-02-12 | |||
| 2014-09-30 | -$15.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$37.79M derived: sum of 2 quarters · filed 2015-11-04 | -$43.55M 10-Q · filed 2015-11-04 | -$50.47M 10-Q · filed 2014-11-04 | -$64.24M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-06-30 | -$21.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | -$27.71M 10-Q · filed 2015-08-04 | -$32.54M 10-Q · filed 2014-08-05 | -$48.41M derived: sum of 3 quarters · filed 2016-02-11 | -$58.04M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2014-03-31 | -$5.76M 10-Q · filed 2015-05-07 | -$8.52M 10-Q · filed 2014-05-08 | -$26.46M derived: sum of 2 quarters · filed 2016-02-11 | -$36.09M derived: sum of 3 quarters · filed 2016-02-11 | $16.91M derived: sum of 4 quarters · filed 2016-02-11 | |||
| 2013-12-31 | -$20.70M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | -$30.33M derived: sum of 2 quarters · filed 2016-02-11 | $22.67M derived: sum of 3 quarters · filed 2016-02-11 | $62.20M 10-K · filed 2016-02-11 | $63.60M 10-K · filed 2014-02-13 | |||
| 2013-09-30 | -$9.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $43.37M derived: sum of 2 quarters · filed 2014-11-04 | $82.89M 10-Q · filed 2014-11-04 | |||||
| 2013-06-30 | $53.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $92.52M 10-Q · filed 2014-08-05 | ||||||
| 2013-03-31 | $39.52M 10-Q · filed 2014-05-08 | |||||||
| 2012-12-31 | -$340.16M 10-K · filed 2015-02-12 | |||||||
| 2011-12-31 | $0.00 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |